Skip to main content

Advances in Clinical Chemistry

  • 1st Edition, Volume 133 - August 1, 2026
  • Latest edition
  • Editor: Gregory S. Makowski
  • Language: English

Advances in Clinical Chemistry, Volume 133 in this ongoing series, examines physiologic and pathophysiologic biochemistry and their impacts on Clinical Chemistry testing and design… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Description

Advances in Clinical Chemistry, Volume 133 in this ongoing series, examines physiologic and pathophysiologic biochemistry and their impacts on Clinical Chemistry testing and design. Molecular mechanisms of disease processes are highlighted in the context of traditional, current, and emerging technologies, and advances in the development of improved diagnostic and predictive biomarkers are examined, especially those targeting early and emerging diseases. Specific chapters in this new release include Drug Induced Renal Injury (DIRI) Biomarkers, Unveiling tobacco markers in exhaled breath, Advances in small extracellular vesicle analysis, Piezoelectric Sensors in Point-of-Care Testing, Mitochondrial myopathy biomarkers, and Hormonal and Metabolic Biomarkers in Long COVID.

Key features

  • Covers emerging markers in drug induced renal injury and mitochondrial disorders
  • Presents technologic advances in breath analysis, biosensor design, and extracellular vesicles
  • Provides updates on detection and treatment challenges with long COVID

Readership

Clinical Laboratory Professionals and Scientists, Physicians, Post-Doctoral Fellows, Research Scientists

Table of contents

1. Drug Induced Renal Injury (DIRI) Biomarkers
Emina Karahmet Sher

2. Unveiling tobacco markers in exhaled breath
Agapios Agapiou

3. Advances in small extracellular vesicle analysis
Wei Zhang

4. Piezoelectric Sensors in Point-of-Care Testing
Miroslav Pohanka

5. Mitochondrial myopathy biomarkers
Roberto Scatena

6. Hormonal and Metabolic Biomarkers in Long COVID
M Dalamaga

Product details

  • Edition: 1
  • Latest edition
  • Volume: 133
  • Published: August 1, 2026
  • Language: English

About the editor

GM

Gregory S. Makowski

Dr Gregory S Makowski is a board-certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President Clinical Laboratory Services Hartford HealthCare in Connecticut.

Affiliations and expertise
Vice President and Chief Scientific Officer, Clinical Laboratory Partners, Newington, CT, USA